<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/818CD6C9-61EE-41F2-9F37-0C7A8F43E25D"><gtr:id>818CD6C9-61EE-41F2-9F37-0C7A8F43E25D</gtr:id><gtr:name>University of Birmingham</gtr:name><gtr:department>Immunity and Infection</gtr:department><gtr:address><gtr:line1>Edgbaston Park Road</gtr:line1><gtr:line2>Edgbaston</gtr:line2><gtr:postCode>B15 2TT</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/818CD6C9-61EE-41F2-9F37-0C7A8F43E25D"><gtr:id>818CD6C9-61EE-41F2-9F37-0C7A8F43E25D</gtr:id><gtr:name>University of Birmingham</gtr:name><gtr:address><gtr:line1>Edgbaston Park Road</gtr:line1><gtr:line2>Edgbaston</gtr:line2><gtr:postCode>B15 2TT</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/27712A22-4A77-441E-920C-DF224E26994E"><gtr:id>27712A22-4A77-441E-920C-DF224E26994E</gtr:id><gtr:firstName>Adam</gtr:firstName><gtr:otherNames>Fidelis</gtr:otherNames><gtr:surname>Cunningham</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/6390AF4F-E65D-46AF-83DB-A6E00A8FFCE0"><gtr:id>6390AF4F-E65D-46AF-83DB-A6E00A8FFCE0</gtr:id><gtr:firstName>Chris</gtr:firstName><gtr:surname>Hewitt</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/BDE65224-702B-4177-91C1-1DA5A739E54C"><gtr:id>BDE65224-702B-4177-91C1-1DA5A739E54C</gtr:id><gtr:firstName>Ian</gtr:firstName><gtr:surname>Henderson</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/80AC6281-0B57-4DCE-AB11-16CA431EA31E"><gtr:id>80AC6281-0B57-4DCE-AB11-16CA431EA31E</gtr:id><gtr:firstName>Jeffrey</gtr:firstName><gtr:surname>Cole</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0900857"><gtr:id>E3772103-D8A4-4714-96BB-FFEB8178FB53</gtr:id><gtr:title>Development of an integrated system for the production and delivery of recombinant biotherapeutics</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0900857</gtr:grantReference><gtr:abstractText>The bacterium E. coli is a standard host for making commercially relevant proteins e.g. recombinant insulin. However, there are limits to the types of protein that can be produced in E. coli. As most of these proteins are not derived from E. coli and are produced at levels much greater than E. coli would normally produce any natural protein, the E. coli bacterium often deals with them by storing the proteins in an inactive form in a compartment of the cell called the inclusion body. The accumulation of proteins in inclusion bodies causes problems for commercial production, including expensive steps to recover the proteins in an active conformation. To overcome these problems some proteins are produced in another compartment of the cell called the periplasm. However, if too much protein is made in the periplasm it can burst the cell open, killing the cell in the process, and therefore little or no protein is produced. Even those that are stable when produced in the periplasm will need expensive purification as there are many other native E. coli proteins in this part of the cell. When expressing a non-native protein the best place for the E. coli bacterium to place the protein is outside of the cell - this prevents accumulation of the protein in inclusion bodies or in the periplasm which might lead to cell death. In addition, the laboratory strains of E. coli produce none, or very little, native proteins outside of the cell. Thus, when proteins are produce outside the cell they are relatively clean and need little cleaning up. However, for a number of technical reasons it has proved to be very difficult to produce proteins outside the bacterial cell. Here we will utilise a very simple system called the Autotransporter system which has a proven track record for producing non-native proteins outside of the cell. We will attempt to optimise the system for a number of commercially relevant proteins.</gtr:abstractText><gtr:technicalSummary>Gene cloning and expression rarely limit the production of recombinant proteins required for the production of biopharmaceutical products, but substantial bottlenecks arise from protein folding, post-translational modifications and secretion. Against this background, it is too often assumed that product recovery and downstream processing present minor technical problems that current technology can overcome. Recent advances in chromatographic techniques make such an assumption reasonable, but only if the protein can be delivered from the fermenter in a soluble form. The primary aim of this proposal is therefore to design a general strategy for the accumulation and secretion of biopharmaceutical proteins. The critical innovative steps will be to exploit three unique properties of autotransporters: their ability to secrete themselves out of bacteria into the surrounding culture fluid; their ability to co-transport partner proteins, for example, a desired biopharmaceutical protein, by a piggy back mechanism; and finally their ability to release the transported protein from the autotransporter itself. In this application we have three primary aims (1) We will specifically determine the components of the autotransporter system that are essential to achieve extracellular release of target proteins (2) We will optimise the system for maximal protein production using traditional microbial physiology techniques. At this juncture, the two major requirements for downstream processing are a dewatering step; and the separation of the desired product from the major contaminant, the bacterial cell. (3) We will apply knowledge from the first two aims to optimise a vaccine strain of Salmonella for delivery of biopharmaceutical proteins in vivo.</gtr:technicalSummary><gtr:fund><gtr:end>2012-10-07</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2009-10-08</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>386878</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Presentation for KTF</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>0A3D70F0-7F5B-41FA-8B66-52109A333776</gtr:id><gtr:impact>Presentation for training individuals in knowledge transfer

Award of a personal fellowship</gtr:impact><gtr:outcomeId>716EC78D606</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>The Guradian Newspaper weekly science Podcast</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>AE394880-F80D-456F-A49E-DA2649F31C1A</gtr:id><gtr:impact>podcast which sparked high levels of p[ublic attendance at the monthly public science talk Cafe Scientifque in Birmingham

none</gtr:impact><gtr:outcomeId>QoMpZURcVvU</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>850000</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Industrial ITN</gtr:description><gtr:end>2017-01-02</gtr:end><gtr:fundingOrg>European Commission</gtr:fundingOrg><gtr:id>EEF1BAAA-0C0E-4F3E-8710-C6461F991324</gtr:id><gtr:outcomeId>cgKpYU51qtz</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>Filed patent covering exploitation of this research for recombinant protein production</gtr:description><gtr:grantRef>G0900857</gtr:grantRef><gtr:id>58CF17B9-6911-4DD5-86A0-2FF2C59D07C4</gtr:id><gtr:impact>This teachnology has been made freely available to the community. It is currently being trialed in industry</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>m-222580703.182686787668f8c2</gtr:outcomeId><gtr:patentId>US7470523 B2</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>Recombinant protein production</gtr:title><gtr:yearProtectionGranted>2014</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>A bacterial expression construct comprises a nucleic acid sequence encoding a secretion unit peptide comprising less than 300 amino acids of the C-terminus of a SPATE-class bacterial autotransporter polypeptide, the secretion unit peptide 5 comprising: (i) the a-helix; (ii) linker; and (iii) ?-barrel region of the ?-domain of the autotransporter polypeptide. Such an expression construct, and associated nucleic acids and peptides, find application in the expression of proteins of interest from a host bacterial cell to the cell culture medium.</gtr:description><gtr:grantRef>G0900857</gtr:grantRef><gtr:id>742F0BE0-A544-422F-879A-C15B408076B0</gtr:id><gtr:impact>Ongoing development with Industrial partners</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>ZX7uqrKX6v5</gtr:outcomeId><gtr:patentId>WO2012110821</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>Protein Secretion</gtr:title><gtr:yearProtectionGranted>2012</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>House of Parliment Infection research awareness</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>2024EFE9-D1A1-4A37-BB6E-E779767E5DC0</gtr:id><gtr:outcomeId>q9z1ijKgPuu</gtr:outcomeId><gtr:type>Participation in a advisory committee</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs><gtr:productOutput><gtr:description>bioprocess</gtr:description><gtr:id>9D6D00CD-A47A-4042-8A73-CCF3409FB12B</gtr:id><gtr:impact>award of a personal fellowship</gtr:impact><gtr:outcomeId>F8722B4CBAA</gtr:outcomeId><gtr:stage>Initial development</gtr:stage><gtr:status>Actively seeking support</gtr:status><gtr:title>bioprocess</gtr:title><gtr:type>Support Tool - For Medical Intervention</gtr:type><gtr:yearDevCompleted>2010</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>improved strains fo rprotein production</gtr:description><gtr:id>35AF6429-DD1F-4411-A20B-2CAEEE1B0FCC</gtr:id><gtr:impact>patent protection granted</gtr:impact><gtr:outcomeId>SfBsSMrmfPJ</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>imporved strains for protein production</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2016</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs><gtr:spinOutOutput><gtr:companyName>Prokarium</gtr:companyName><gtr:description>Spin-out company developing vaccines</gtr:description><gtr:id>060844EE-34A1-48D5-A62A-8F2E7355DDB4</gtr:id><gtr:impact>company based on live attenuated vaccines</gtr:impact><gtr:outcomeId>dEJEo16wQNz</gtr:outcomeId><gtr:yearCompanyFormed>2011</gtr:yearCompanyFormed></gtr:spinOutOutput></gtr:spinOutOutputs></gtr:output><gtr:publications><gtr:publication><gtr:id>A2B2A341-18EF-4FB8-BD5F-05451DA3D4E2</gtr:id><gtr:title>SadA, a trimeric autotransporter from Salmonella enterica serovar Typhimurium, can promote biofilm formation and provides limited protection against infection.</gtr:title><gtr:parentPublicationTitle>Infection and immunity</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b7f3c5ac0ed294dcd0579e4e10906042"><gtr:id>b7f3c5ac0ed294dcd0579e4e10906042</gtr:id><gtr:otherNames>Raghunathan D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0019-9567</gtr:issn><gtr:outcomeId>qNyw2G14r59</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CC38B73D-0C53-4810-B2CD-3BCE0B9D524C</gtr:id><gtr:title>T-zone localized monocyte-derived dendritic cells promote Th1 priming to Salmonella.</gtr:title><gtr:parentPublicationTitle>European journal of immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/47167a5a3616b6be880b3d2e16a7ecb3"><gtr:id>47167a5a3616b6be880b3d2e16a7ecb3</gtr:id><gtr:otherNames>Flores-Langarica A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0014-2980</gtr:issn><gtr:outcomeId>sPo27N6VPjh</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0C2A676A-8492-4F10-ABC8-2092AF0498FA</gtr:id><gtr:title>CD31 is required on CD4+ T cells to promote T cell survival during Salmonella infection.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a8815e62a6f3fd63500acb52e99dbbeb"><gtr:id>a8815e62a6f3fd63500acb52e99dbbeb</gtr:id><gtr:otherNames>Ross EA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>Rn2ceE27vdK</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5E0ADFC8-0A49-41C3-A573-06680082CEDA</gtr:id><gtr:title>Genome sequence of the emerging pathogen Aeromonas caviae.</gtr:title><gtr:parentPublicationTitle>Journal of bacteriology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/70975aec0fd2cb9270bf0037604c252c"><gtr:id>70975aec0fd2cb9270bf0037604c252c</gtr:id><gtr:otherNames>Beatson SA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0021-9193</gtr:issn><gtr:outcomeId>W5UpLms4tCc</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>67B80079-8638-440E-8F32-8E916E18AA4B</gtr:id><gtr:title>Absent bactericidal activity of mouse serum against invasive African nontyphoidal Salmonella results from impaired complement function but not a lack of antibody.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/228b8552733022b0a8c1779f91099f6e"><gtr:id>228b8552733022b0a8c1779f91099f6e</gtr:id><gtr:otherNames>Siggins MK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>npqxVU3LUxR</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>632F2CDF-3ADB-487F-90DD-D0EC1E1897E1</gtr:id><gtr:title>The unusual extended signal peptide region is not required for secretion and function of an Escherichia coli autotransporter.</gtr:title><gtr:parentPublicationTitle>FEMS microbiology letters</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9c3512b8ed2141f5ee07228a27a3d33a"><gtr:id>9c3512b8ed2141f5ee07228a27a3d33a</gtr:id><gtr:otherNames>Leyton DL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0378-1097</gtr:issn><gtr:outcomeId>kaNWzt9peZE</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9061531F-3E57-42E8-BD90-DC9367A4936D</gtr:id><gtr:title>A generalised module for the selective extracellular accumulation of recombinant proteins.</gtr:title><gtr:parentPublicationTitle>Microbial cell factories</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9675826989b0dde130f03bd16e7a3851"><gtr:id>9675826989b0dde130f03bd16e7a3851</gtr:id><gtr:otherNames>Sevastsyanovich YR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1475-2859</gtr:issn><gtr:outcomeId>pm_15858_28_22640772</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>007830BB-DAB1-44D3-BB36-EEBFA010846E</gtr:id><gtr:title>Interaction of FkpA, a peptidyl-prolyl cis/trans isomerase with EspP autotransporter protein.</gtr:title><gtr:parentPublicationTitle>Gut microbes</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/73b66e4e6fffac77dad2486d38b2186c"><gtr:id>73b66e4e6fffac77dad2486d38b2186c</gtr:id><gtr:otherNames>Ruiz-Perez F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1949-0976</gtr:issn><gtr:outcomeId>UhCbtGpBUm6</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>19215050-0E40-42AE-8C5E-AE979E7BAFC1</gtr:id><gtr:title>Thymic function is maintained during Salmonella-induced atrophy and recovery.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a8815e62a6f3fd63500acb52e99dbbeb"><gtr:id>a8815e62a6f3fd63500acb52e99dbbeb</gtr:id><gtr:otherNames>Ross EA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>pm_15858_28_22993205</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4C2A9BD6-403B-4308-B6D5-2651A4D111C2</gtr:id><gtr:title>Soluble flagellin, FliC, induces an Ag-specific Th2 response, yet promotes T-bet-regulated Th1 clearance of Salmonella typhimurium infection.</gtr:title><gtr:parentPublicationTitle>European journal of immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/090770ae85e08aea4f8baa330abeb34d"><gtr:id>090770ae85e08aea4f8baa330abeb34d</gtr:id><gtr:otherNames>Bobat S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0014-2980</gtr:issn><gtr:outcomeId>jKnZDWegi4T</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2CC9C767-58B2-430D-A00E-637228269359</gtr:id><gtr:title>The capsular polysaccharide Vi from Salmonella typhi is a B1b antigen.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/38e50117f77a619640c23aad9a8a1599"><gtr:id>38e50117f77a619640c23aad9a8a1599</gtr:id><gtr:otherNames>Marshall JL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>pm_15858_28_23162127</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E828EA9C-EF50-4D9D-AB7F-F277332510AC</gtr:id><gtr:title>Systemic flagellin immunization stimulates mucosal CD103+ dendritic cells and drives Foxp3+ regulatory T cell and IgA responses in the mesenteric lymph node.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/47167a5a3616b6be880b3d2e16a7ecb3"><gtr:id>47167a5a3616b6be880b3d2e16a7ecb3</gtr:id><gtr:otherNames>Flores-Langarica A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>pm_15858_28_23152564</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7C4F9000-69CA-45E3-9857-DFB4B6E9FA92</gtr:id><gtr:title>Transcription of the plasmid-encoded toxin gene from enteroaggregative Escherichia coli is regulated by a novel co-activation mechanism involving CRP and Fis.</gtr:title><gtr:parentPublicationTitle>Molecular microbiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cb9dfa9aa2f32e433b47efe8cb7aa7f4"><gtr:id>cb9dfa9aa2f32e433b47efe8cb7aa7f4</gtr:id><gtr:otherNames>Rossiter AE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0950-382X</gtr:issn><gtr:outcomeId>BXiybXNnDUE</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>87E542BB-B91E-48B4-8726-7086D40F4475</gtr:id><gtr:title>Complete genome sequence of the Crohn's disease-associated adherent-invasive Escherichia coli strain HM605.</gtr:title><gtr:parentPublicationTitle>Journal of bacteriology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/498e5c5e03c2f41f7b91d5f863b1ad16"><gtr:id>498e5c5e03c2f41f7b91d5f863b1ad16</gtr:id><gtr:otherNames>Clarke DJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0021-9193</gtr:issn><gtr:outcomeId>hptUNahQhLj</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0900857</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>C6D70A71-8796-47BC-AFE0-CC2286E66A06</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Inflammatory and Immune System</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>CF950C9A-DB16-4E23-8AEB-94548777BCA1</gtr:id><gtr:percentage>25</gtr:percentage><gtr:text>1.1  Normal biological development and functioning</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>D8F3A27D-084A-40BB-A046-087DACE23410</gtr:id><gtr:percentage>25</gtr:percentage><gtr:text>3.4  Vaccines</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>8F896112-5A04-4A11-A9F0-2B446D9AAC8A</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>5.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>